Indication intelligence, analysis and sector perception

RegMed Investors (RMI) Research Note: BrainStorm Cell Therapeutics Inc. (BCLI) Registered Direct Offering of 4,054,055 M shares priced at $1.85 raising $7.5 M

July 17, 2023 11:17am

BCLI closed Friday at $1.97 and is down -$0.05 at $1.92 in the morning session

Maxim Group LLC is acting as the sole placement agent for the offering.

Entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,054,055 shares of the BCLI's common stock and warrants to purchase up to an aggregate of 4,054,055 shares of common stock in a registered direct offering.

Each share of common stock is being offered in the offering together with a warrant to purchase one share of common stock at an offering price of $1.85 per share.

· The warrants will have an exercise price of $2.00 per share, will be immediately exercisable and will expire five years from the date of issuance.

The offering is expected to close on or about July 19, 2023, subject to satisfaction of customary closing conditions.

The Bottom Line: Desparate - NO real significant data

52-week low of $1.09 and a high of $4.70

Outstanding shares: 39.41 M

Float: 32.71 M

Short ratio: 9.47

Short percentage of Flat: 7.62%

Cash: $2.23 M

Debt: $3.68 M

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.